Objective:

To evaluate the efficacy and tolerability of iron protein succinylate (IPS) compared to conventional oral iron supplementation, particularly focusing on its advantages in patients with iron deficiency and iron deficiency anemia.

Key Findings:

• IPS produced a higher clinical response rate (79% vs 68%) and fewer adverse events (12% vs 26%) compared to controlled-release ferrous sulfate, indicating better tolerability.
• IPS achieved 19% iron absorption in blood donors, significantly higher than 6% for ferrous sulfate, highlighting its superior absorption capacity.
• IPS showed greater increases in hemoglobin and red blood cell indices in women with iron deficiency compared to ferrous sulfate, suggesting its effectiveness in this demographic.

Interpretation:

IPS offers a potentially superior alternative to conventional oral iron therapies, with improved tolerability and absorption, particularly in patients with inflammatory conditions, which may influence treatment choices.

Limitations:

• Many studies included were older and had relatively small sample sizes, which may affect the reliability of the findings.
• Mixed findings in pregnant patients regarding hemoglobin improvement suggest the need for further research in this area.

Conclusion:

IPS presents an effective and better-tolerated option for treating iron deficiency, particularly in patients with inflammatory conditions, although some patients may still require intravenous iron therapy.